In response to an EU Consultation on the future of the single market in pharmaceuticals for human use, Eurordis has put forward recommendations specifically focused on orphan drugs. The Contribution document proposes measures to:
- assess therapeutic added value and to establish reference pricing on a global level;
- upgrade incentives on a national and EU level;
- continue support for research and development of orphan drugs.
These measures aim at ensuring transparency and equality of access to orphan drugs across the EU and beyond.